Clinical Trial 43484

Peoria, AZ 85381


Study 43484 Flyer
Click image to enlarge

Bond Avillion 2 Development LP (Avillion) has begun a study of an investigational drug called PT027 (also known as the “study drug”), which is a combination of budesonide and albuterol sulfate (BDA) given in a metered-dose inhaler (MDI) as a possible treatment for asthma symptoms. An MDI is a device that delivers a measured amount of medication as a mist that the patient can inhale. An MDI consists of a pressurized canister of medication in a case with a mouthpiece. MDIs are portable, efficient, and convenient. This investigational drug combination delivers 2 well-established asthma treatments. Budesonide is a well-established corticosteroid treatment that suppresses immune response, such as reducing swelling and tightening of airways. Many patients take budesonide regularly as a “controller” medication to control chronic symptoms and prevent asthma attacks. Albuterol is known in many countries as salbutamol.  Albuterol/salbutamol is a treatment that is widely used as needed for short-term treatment of asthma symptoms, or a “reliever” medication. It is expected that this investigational drug combination will be better at preventing severe asthma attacks compared to some standard “reliever” medications.

Qualified Participants May Receive:

You will be reimbursed $100 for each completed study visit. You will be reimbursed at each visit.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.